The push to get promising drugs to patients as quickly as possible, while addressing potential safety concerns, led to the formation of the FDA's accelerated approval program, which was established in 1992. Congress passed the US Food and Drug Administration (FDA) Amendments Act of 2007 to address potential safety concerns that can arise after a drug has received accelerated approval. In order to ensure compliance, the FDA could impose civil monetary penalties of up to $10 million on drug...

We have been developing a AI methods that are specifically focused on answering questions related to oncology drug development. One challenge for antibody drug conjugates (ADCs) is understanding how we can improved the clinical success rates for ADCs. By understanding why certain ADCs fail in the clinic, perhaps this can help guide the next generation of ADCs, which will hopefully address some of the limitations of the current wave of ADCs. ADCs are complex molecules consisting of an antibody...

Cancer remains one of the most complex and challenging diseases to treat. Developing new oncology drugs is a lengthy, costly, and uncertain process. Yet, artificial intelligence (AI) is reshaping how researchers approach drug discovery, offering new tools to accelerate progress and improve outcomes. This post explores how integrating AI into the oncology drug discovery workflow is transforming the field, highlighting practical examples and key benefits. AI-driven oncology drug discovery in a...